Market Positioning and Competitive Advantages The pharmaceutical landscape increasingly demands innovative solutions that address complex metabolic disorders comprehensively
With files from Jennifer La Grassa, The Canadian Press and Reuters
Overweight or obese
Sickle Cell Disease: A Distinction of Two Most Frequent Genotypes (HbSS and HbSC) PLoS ONE
Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling
Semaglutide Not Associated with Increased Risk of Eye Disorders, 19 August 2025, The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION), 27 June 2025, WHO, PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, 06 June 2025, European Medicine Agency, Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan, does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy